Eclipsemed Partners with Human Med To Introduce Revolutionary Body-Jet® System

State of the Art Water-Jet Assisted Liposuction Technology

(Dallas, TX) Eclipsemed Ltd, a leading national distributer of advanced medical and aesthetic equipment, and Human Med AG, of Germany, a leading manufacturer of medical and aesthetic devices have introduced a revolutionary new liposuction technology, Body-Jet®. Body-Jet provides a novel approach to removing fat by utilizing a gentle and controlled sequence of pulsed sprayed saline to dislodge mainly intact fat cells. This new approach affords a less traumatic liposuction experience for patients with often times less discomfort and downtime. In many cases general anesthesia is not necessary.

While traditional liposuction basically destroys fat cells, the Body-Jet loosens fat without requiring impact on the fat cell itself. It uses a gentle jet of water to navigate through the internal tissue, a process which until now, required manual force from the surgeon. This process allows the surgeon to use approximately 10% of the energy typically required for fat removal, which is much gentler and less traumatic for the patient.

Additionally, the science behind Body-Jet’s method of water-liposuction allows for better assessment of new contours during surgery which greatly reduces the number of corrective procedures that need to be performed.

The Body-Jet allows the suction cannula to freely move within the fat compartment with minimized trauma to the fat cells and the surrounding structures. This new method and cannula simultaneously irrigates and aspirates fat issue. The Body-Jet uses only 25% of the infiltration fluid usually required for standard liposuction. This reduction in fluid and gentler manipulation results in less swelling, improved patient comfort and decreased trauma to tissue, nerves and blood vessels. The septal attachments between the deeper structures and the skin are preserved which aids in a more naturally tightened and contoured result.

Older liposuction techniques and even the newer “fat-melting” procedures still require aggressive back and forth motion and fat must be aspirated or suctioned out. This trauma to the patient can often time lead to bleeding, nerve damage, lumps, bumps, divots and rupture of the septal attachments. With Body-Jet, patients experience little discomfort, quick healing and visibly precise results.

Hartmut Meyer, MD, of Germany, one of the pioneers of water-assisted liposuction, has successfully performed over 1500 procedures worldwide and has been training physicians and surgeons throughout the U.S. Robert H. Gotkin, MD, board certified plastic surgeon and attending physician at the New York Eye and Ear Infimary in New York City, has been using the Body-Jet system and his patients are thrilled with the outcome. “I find the Body-Jet to be a very gentle, extraordinarily effective and minimally invasive method of liposuction. It is a much less aggressive procedure for both the doctor and patient. In my opinion, Body-Jet is considerably less traumatic than traditional liposuction.”

About Eclipsemed Ltd.
Eclipsemed is a leading distributor of aesthetic high-tech medical devices and supplies. Eclipsemed has established a reputation as a leader on the national aesthetic market scene. The recent launch of DOT Therapy is the most current example of how Eclipsemed has established itself as a leading force in bringing innovative products to market. Through its own direct sales force and team of independent agents, Eclipsemed continues to introduce products and solutions to the aesthetic marketplace.

Eclipsemed Ltd.
800.759.6876
www.eclipsemed.com

Source: Eclipsemed Ltd.

Celebrities Help Grant Wishes at LATISSE Wishes Launch Event in Hollywood

(IRVINE, Calif., March 27, 2009) – Allergan, Inc. (NYSE: AGN) hosted a star-studded event last night in Hollywood to launch LATISSE Wishes, a charitable public awareness campaign designed to help make wishes come true. Actress Brooke Shields and beauty expert to the stars Anastasia Soare will lead the campaign to generate $1 million to support the Make-A-Wish Foundation, a non-profit organization dedicated to granting the wishes of children with life-threatening medical conditions.

The LATISSE Wishes campaign was borne out of the tradition of blowing on an eyelash to make a wish come true and leverages the excitement surrounding the availability of Allergan’s LATISSE (bimatoprost ophthalmic solution) 0.03%, the first and only science-based prescription treatment approved by the U.S. Food and Drug Administration for hypotrichosis of the eyelashes (inadequate or not enough lashes) that is used to grow eyelashes, making them longer, fuller and darker.

“In the short time LATISSE has been available, the product has already made many women’s wish lists,” said David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan. “While LATISSE may fulfill the wish for more prominent eyelashes, we also wanted to shine the spotlight on the Make-A-Wish Foundation and provide support for the important work it does in granting children’s wishes.”

The LATISSE Wishes campaign launched with an initial donation of $500,000 from Allergan to the Make-A-Wish Foundation. Consumers are encouraged to help double this amount to $1 million by registering their support at www.LATISSE.com to help grant the wishes of children in their local communities. Between now and December 31, 2009, Allergan will donate $5 for each new visitor who registers online, up to an additional $500,000.

“Every 40 minutes the Make-A-Wish Foundation grants a wish to a child with a life-threatening medical condition. Forty seconds is all it takes to visit www.LATISSE.com to register your support and help make wishes come true,” said David Williams, president and chief executive officer of the Make-A-Wish Foundation. “We urge everyone to log on to the LATISSE™ Web site and register their support to help grant the wishes of children in their communities.”

“I am delighted to be a part of LATISSE Wishes, to not only help educate women on an eyelash growth product that is the first to be scientifically proven, but also to support a worthy organization such as the Make-A-Wish Foundation,” said Shields. “I remember being a child and blowing on an eyelash hoping my wish would come true, and as a mother I’ve passed this tradition onto my children. Through LATISSE Wishes and in partnership with the Make-A-Wish Foundation, we can keep the tradition alive and fulfill the hopes of so many more children around the country.”

In addition to Shields and Soare, other stars including Debra Messing, Angie Harmon, Marisa Tomei, Mandy Moore, Debi Mazar, Jewel, Jennifer Coolidge and Perrey Reeves attended last night’s red-carpet kick-off event for the LATISSE Wishes campaign. Over the next several months, campaign ambassadors Shields and Soare, who both use LATISSE solution, will travel to cities across the country hosting informational events aimed to further support the campaign and its goal of providing $1 million to the Make-A-Wish Foundation. Local events will be held in New York, Miami, Dallas, Minneapolis and San Francisco.

“In my business I constantly work to help make women’s beauty wishes come true and now we can help children’s wishes come true through the LATISSE Wishes campaign,” said Soare. “I am excited to bring this worthy campaign to cities across the country.”

For more information about the LATISSE Wishes charitable awareness campaign, please visit www.LATISSE.com.

About LATISSE
LATISSE (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. The once-daily prescription treatment is applied to the base of the upper eyelashes with a sterile single-use-per-eye disposable applicator. While individual results may vary, LATISSE users can expect to experience results in as little as eight weeks, with significant results in 16 weeks. To maintain effect, continued treatment with LATISSE solution is required, and if use of LATISSE is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of several weeks to months (average eyelash hair cycle).

Important LATISSE Information
LATISSE (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.

LATISSE Important Safety Information
Do not use LATISSE solution if you are allergic to one of its ingredients.

LATISSE solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. If you have a history of abnormal intraocular pressure (IOP), you should only use LATISSE under the close supervision of your physician.

LATISSE use may cause darkening of the eyelid skin which may be reversible. LATISSE use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

If a patient is using other prescription products for lowering eye pressure or have a history of eye pressure problems, use LATISSE under close physician supervision.

If you develop or experience any eye problems, eyelid reactions, or have eye surgery, consult your physician immediately about continued use of LATISSE.

The most common side effects after using LATISSE solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE solution may cause other less common side effects which typically occur on the skin close to where LATISSE is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.

About Make-A-Wish Foundation
The Make-A-Wish Foundation grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Founded in 1980 when a group of caring volunteers helped a young boy fulfill his dream of becoming a police officer, the Foundation is now the largest wish-granting charity in the world, with 66 chapters in the United States and its territories. With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 174,000 wishes in the United States since its inception. For more information about the Make-A-Wish Foundation, visit wish.org and discover how you can share the power of a wish.

About Allergan, Inc.
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential - to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its Total Facial Rejuvenation portfolio, including BOTOX Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical also offers the industry’s widest range of silicone gel-filled and saline-filled breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.

Allergan Medical
800.433.8871
www.latisse.com

Source: Allergan Medical

Ophir-Spiricon Inc. Releases New Catalog for Laser Meter Measurement Applications

March 25, 2009 - Logan, UT - Ophir-Spiricon, the global leader in precision laser measurement equipment, today announced the release of its 2009 Laser Measurement Catalog covering a wide range of laser power/energy measurement instruments and beam diagnostics for medical, industrial, and research applications. The catalog is an encyclopedic reference that covers virtually all laser measurement and analysis needs, from photodiode, thermal, and pyroelectric power/energy detectors to portable displays and high power, high accuracy beam profilers.

The 2009 catalog provides in-depth technical articles on laser power and energy meters, as well as information about the company’s newest products, such as BeamGage™, the next generation laser beam analysis system that integrates beam simulator, automatic camera control, and custom algorithms.

The catalog also features PE50-DIF Pyroelectric Detector, the first laser power/energy detector to combine high damage threshold and high repetition rates with the widest range of wavelengths in the industry, from UV to Near IR, and Pyrocam™ III Pyroelectric Array Camera, the only 2D sensor for imaging real-time Terahertz applications.

“As lasers become increasingly commonplace in consumer and industrial applications, the need grows for a comprehensive reference that will cover essential laser measurement principles and systems,” stated Ephraim Greenfield, VP Engineering, Laser Measurement Group, Ophir-Spiricon, Inc.

“The 2009 catalog provides tutorials on power/energy measurement and beam profiling. In addition, it highlights some of the greatest advances in the field of laser measurement, including the II-IV-CO2-58, the industry’s first real-time, high power CO2 laser beam profiler. The YAG Focal Spot Analyzer is the only real-time system for measuring focus spot characteristics of high power lasers. And the PE9-F Pyroelectric Detector measures repetitive pulses at the highest rate, 25 KHz.”

Laser Measurement Products & Tutorials

The 2009 Ophir-Spiricon Laser Measurement Catalog covers Ophir-Spiricon’s entire range of state-of-the-art measurement products, organized into four categories:

* Heads: including pyroelectric, photodiode, and RP heads

* Displays: including the Nova II, Orion, and Vega handhelds with wireless Bluetooth interfaces

* Beam Profiling: including BeamGage and the world famous Laser Beam Analysis profiler

* OEM Products: the principal products used in medical and industrial laser systems

Request a Catalog

The 2009 Ophir-Spiricon Laser Measurement Catalog is free of charge.

It can be downloaded at: http://www.ophir-spiricon.com or

You can receive a printed copy by calling +1 435-753-3729.

About Ophir-Spiricon
Established in 1978, Ophir-Spiricon is part of the Ophir Optronics Laser Measurement Group. The Laser Measurement Group provides a complete line of instrumentation including power and energy meters, beam profilers, and spectrum analyzers. Dedicated to continuous innovation in laser measurement, the company holds a number of patents, including Ultracal™, the baseline correction algorithm that helped establish the ISO 11146-3 standard for beam measurement accuracy. The company’s modular, customizable solutions serve manufacturing, medical, military, and research industries throughout the world.

Ophir-Spiricon
800.383.0814
www.ophir-spiricon.com

Source: Ophir-Spiricon

Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice.

The Merz Scales™ Are the First Ever Standardized Scales to Measure the Skin’s Aging Process

Merz Aesthetics, a division of Merz Pharmaceuticals USA, introduced The Merz Scales – the first standardized, comprehensive rating system that measures, helps educate, and provides a common language for physicians, researchers and patients on the skin’s aging process – at the American Academy of Dermatology’s (AAD) 67th annual meeting in San Francisco. Developed by a leading team of multidisciplinary experts, the Merz Scales address the need for standardization, validation, and consistency when evaluating changes in aging skin. While the scales do not diagnose or treat any particular conditions, they do facilitate education and communication between physicians and patients about the aging process.

“At Merz we believe in the science of aesthetic medicine,” said Jack Britts, President and Chief Executive Officer, Merz Pharmaceuticals USA. “Providing tools such as the Merz Scales to researchers, clinicians and patients enables us to bring an objective measure to the management of the aging process that can help educate and inform healthcare professionals and their patients. After years of having no comprehensive scale we need to bring new science to the aesthetics business.”

The Merz Scales, including A Validated Brow Positioning Grading Scale; A Validated Grading Scale for Forehead Lines; A Validated Lip Fullness Grading Scale; A Validated Grading Scale for Marionette Lines; A Validated Hand Grading Scale; and, A Validated Grading Scale for Crow’s Feet were published in a special issue of Dermatologic Surgery in November 2008. The Merz Scales were presented at several poster sessions at the AAD annual meeting, including e poster 3517, A Validated Rating Scale for Marionette Lines; e poster 3518 – A Validated Hand Grading Scale; e poster 3520 – A Validated Lip Fullness Rating Scale; and e poster 3523 – A Validated Rating Sale for Crow’s Feet.

Other scales being developed by Merz Aesthetics include measures for glabellar lines, nasolabial folds, décolletage, and facial volume loss.

“The importance of these scales can’t be overestimated – in the last decade there has been a 446% increase in the number of cosmetic procedures that are performed. And this translates into an enormous number; more doctors, many, many, many more patients and researchers – all of whom are trying to have a common language to describe to each other the traits of aging as time goes by,” said Jean Carruthers, MD, a lead author and clinical professor of ophthalmology at the University of British Columbia, Canada.

About the Merz Scales
A total of nine experts from around the world trained in multiple specialties (dermatology, ophthalmology, plastic surgery, and dermatologic surgery) came together to create and validate a comprehensive scale system, reviewing and including photographs of men and women of diverse ages, skin types and ethnicities. As part of this process, the experts rated 35 to 50 real-life images of people, and evaluated the images for reproducibility of results.

The Merz Scales were then generated as five-point scales using computer-morphed photography. Specific anatomical changes related to aging were identified and were incorporated into the photographs, and a series of visual guides were developed to correspond to regional areas on the face and hands. When “lines” were formed as a result of the different movements of different muscle groups, such as crow’s feet and forehead lines, static and dynamic lines were included. For example, The Forehead Lines Grading Scale was developed to objectively quantify resting (static) and hyperkinetic (dynamic) forehead lines. The scale ratings are 0 for no wrinkles, 1 for no wrinkles present at rest but fine lines with facial expressions, 2 for fine wrinkles present at rest and deep lines with facial expression, 3 for fine wrinkles present at rest and deeper lines with facial expression and 4 for deeper wrinkles at rest and deeper furrows with facial expression.

During the development of the validation process the team of experts discussed the resulting scales. Every participant graded the scales twice, with an overnight break in between. Intra and interrater variability analysis was performed. The variability analysis also was depicted in a bubble plot, which is an informative way of comparing grading between raters.

About Merz Aesthetics
Merz Aesthetics is the new division of Merz Pharmaceuticals, part of the Merz group of companies based in Frankfurt Germany, with a 100-year history of compassion and innovation in healthcare. The ongoing development of The Merz Scales represents the company’s ongoing, deep commitment to education and research in health and beauty.

Merz Aesthetics plans to bring Merz’ commercially successful line of injectable HA (hyaluronic acid) dermal fillers, called Belotero® to the US, once approved for marketing by the United States Food and Drug Administration (FDA). Belotero products are manufactured using a unique production process called Cohesive Polydensified Matrix (CPM) technology. This makes Belotero the world’s first cohesive polydensified monophasic dermal filler. Merz hopes to introduce Belotero dermal fillers to the US market in early 2010, pending completion of clinical trials and following approval by the FDA.

Merz Aesthetics
888.MERZ.USA (637-9872)
www.merzscales.com

Source: Merz USA

SkinMedica Launches New Hydrating Complex™

Provides long-term hydration with Hyaluronic Acid

New York, NY – March 10, 2009 – SkinMedica, Inc. launches an intense new serum that works to retain moisture and prevent future water loss.

Superior to other serums of this type, Hydrating Complex™ boasts both high and low molecular weight hyaluronic acid (HA)—the higher weight stays above the skin to provide instant hydration as the HA holds 40 times its weight in water, while the lower weight penetrates the skin to restore its moisture reservoir. The inclusion of a hyaluronidase inhibitor prevents the breakdown of HA to prolong moisture and the breakdown of elastin resulting in newfound firmness. This innovative treatment also contains three natural sugar compounds to stimulate skin’s natural production of HA.

When used in conjunction with daily moisturizer, the result is a more youthful, glowing, and firmer appearance.
______________________________________________________________________

CLINICAL STUDY:

In a recent clinical study, 45 women with self-perceived normal to dry skin used Hydrating Complex for 28 days and discovered the following results:

• Immediately after applying the product, 100% of subjects felt their skin was softer and 94% felt it improved the hydration of their skin
• With continued use, 94% saw an improvement in smoothness and moisture level in their skin
• Overall, 82% of participants communicated excellent or good satisfaction with the product
______________________________________________________________________

Hydrating Complex™ launches in April 2009 and is available nationwide at doctor’s offices and medically supervised spas.

SkinMedica, Inc. is an aesthetic and pharmaceutical company focused on developing, acquiring and commercializing products that improve the appearance of skin and treat dermatologic conditions and diseases.

SkinMedica
877.944.1412
www.skinmedica.com

Source: SkinMedica

Cutera to Preview New ADS Technology At AAD

BRISBANE, Calif., (GLOBE NEWSWIRE) — Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, will preview its exclusive Adjustable Depth Selectivity (ADS) Technology at the 67th Annual Meeting of the American Academy of Dermatology in San Francisco, March 6-10, 2009.

Cutera’s ADS Technology is the culmination of five years of clinical research and collaboration for non-invasive body contouring. The two key features of this technology are the ability to selectively target and heat fat cells and to vary treatment depths within the fat. These combined effects are expected to result in non-invasive body contouring for a wide range of patients.

Research conducted with in-vitro human fat cells at the Cell Culture Facility at the University of California Medical Center, San Francisco (UCSF) determined fat cell survival rates following thermal exposures. This research was necessary to establish treatment parameters.

In a separate, in-vivo human study, Timothy H. McCalmont M.D., a dermatopathologist at UCSF, evaluated histology samples and said, “The samples showed controlled cell death in adipose tissue and full protection of overlying cutaneous tissue.”

Kevin Connors, president and CEO of Cutera, explains, “To address non-invasive body contouring, we recognize the importance of delivering uniform heat selectively to the fat cells, while adjusting for varying depths and thicknesses of the fat layer. We are continuing our clinical research and look forward to incorporating this technology into our product portfolio in the second half of the year.”

About Cutera, Inc.
Brisbane, Calif.-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients.

Cutera, Inc.
888.4CUTERA (428-8372)
www.cutera.com

Source: Cutera

American Academy of Dermatology 67th Annual Meeting will be held March 6 - 10, 2009 in San Francisco

SAN FRANCISCO - The American Academy of Dermatology (Academy) will hold its 2009 Annual Meeting in San Francisco, March 6-10, 2009, at the Moscone Center. With an anticipated attendance of more than 17,000, this meeting will feature world-renowned leaders in the field of dermatology and presentations on the latest research in the diagnosis and medical, surgical and cosmetic treatment of skin, hair and nail conditions.

This year’s Plenary Session will be on Sunday, March 8, and will begin with Roderick J. Hay, MD, FAAD, who will present the Clarence Livingood Lectureship, “Global Health — Where Does Dermatology Stand?” Kevin D. Cooper, MD, FAAD will deliver the Marion Sulzberger Lectureship, and John Mendelsohn, MD, will present the Lila Gruber Lectureship, “Targeting The EGF Receptor for Personalized Cancer Therapy.” This year’s Eugene J. Van Scott Award for Innovative Therapy of the Skin will go to John Voorheees, MD, who will also deliver the Phillip Frost Leadership Lecture. Dr. Voorhees will present “Aging Skin: Mechanism-Based Interventions.” Veteran ABC news correspondent Sam Donaldson — who talked about skin cancer at our Burden of Skin Diseases Forum at the Academy’s 2007 Annual Meeting in Washington, D.C., returns to deliver another poignant message as our guest Plenary speaker.

Each year the Academy raises the educational bar, adding new and innovative courses to meet the needs of today’s dermatologists. The Academy’s aim, as always, is to create the broadest range and zero in on the hottest topics. In San Francisco, you’ll discover many new offerings in very diverse and global arenas, such as gender dermatology, international dermatology, aquatic dermatology, tropical dermatology and sports dermatology. You’ll find courses that offer practice management insights covering everything from legal and ethical issues to office design. You’ll also gain new insights on a host of skin conditions, exciting new clinical trials, and new treatment options.

Additionally, special sessions have been added for Maintenance of Certification. Audience response systems and case presentations have been added to the program to enhance interactions with the speakers. There are also workshops and live patient demonstrations that offer an alternative to lecture formats.

As you plan your schedule for San Francisco, take full advantage of the multi-faceted, diverse educational opportunities that await you at the premiere educational event in dermatology. On behalf of the Scientific Assembly Committee, I hope this meeting in San Francisco changes your life and reaffirms your dedication to our profession of dermatology. The program is designed to do no less.

American Academy of Dermatology
888.462.DERM (3376)
www.aad.org

Source: AAD

New Research Finds Six Factors Predictive of Melanoma Risk

Outdoor summer jobs during the teen years among risk factors.

San Francisco (Mar 5, 2009) — Melanoma, the most serious form of skin cancer, is a health risk that accounts for more than 75 percent of all skin cancer deaths, according to the American Cancer Society (ACS). Looking at this sobering statistic another way, it is estimated that one American dies from melanoma almost every hour (every 62 minutes). While those at higher risk of developing melanoma typically have included fair-skinned individuals who sunburn but don’t tan easily and have a history of sunburns, new research has identified other factors that could increase a person’s risk of melanoma.

Speaking today at the 67th Annual Meeting of the American Academy of Dermatology (Academy), dermatologist Darrell S. Rigel, MD, FAAD, clinical professor of dermatology at New York University Medical Center (NYU) in New York, presented new research which identifies six factors that independently predicted melanoma risk in 600 people.

“Since we haven’t identified the gene responsible for melanoma yet, we can’t screen people with this gene who we know would be at risk for melanoma,” said Dr. Rigel. “Similar to how those with the known BRCA2 gene are carefully screened for breast cancer, we hope to one day be able to screen people that carry the melanoma gene. Until then, we have to rely on indirect measures or risk factors that we know are common to people who develop melanoma to try to educate those individuals to get regular skin exams by their dermatologist.”

In a pre-published study conducted by Dr. Rigel and a colleague at NYU Medical Center, data from characteristics of 600 people – including 300 melanoma patients and 300 control patients (those who had not had melanoma) – were examined to try to determine what factors varied between the two groups and were most often linked to melanoma. From this research, Dr. Rigel created a new model of six factors that independently predicted melanoma risk which could be used as a quick screening method for people to assess their own risk.

The six factors Dr. Rigel identified, which include some melanoma risk factors that have been previously identified, are as follows:

1. History of blistering sunburns as a teenager
2. Red or blonde hair
3. Marked freckling of the upper back – a sign of excessive sun exposure and that a person is susceptible to it
4. Family history of melanoma
5. History of Actinic Keratoses (AKs) – considered the earliest stage in the development of skin cancer
6. Outdoor summer jobs for three or more years as a teenager

“When conducting this study, we looked at 43 different factors and these six factors independently predicted melanoma risk,” said Dr. Rigel. “In the average U.S. population, the lifetime melanoma risk is about 1.5 percent for an invasive melanoma and about 3 percent for all types when you include in situ melanomas. So if you have any one of these six factors, your melanoma risk goes up to about a twofold to threefold increase over the general population – or roughly a 3 percent to 5 percent lifetime risk of developing melanoma with any one of those factors.”

Dr. Rigel added that for individuals with two or more of these factors, the risk goes up to a five to 10 times increased lifetime risk of melanoma over the general population. In addition, those with any three or more of these six factors have up to a 10 to 20 times increased risk of developing melanoma.

Other previous studies examining risk factors for melanoma have shown correlations between melanoma and a range of associations – from certain types of cancers to socioeconomic class. Examples of these previous studies include:

* Women and men with a prior history of breast cancer have a twofold to threefold risk of developing melanoma.
* Women with a prior history of thyroid cancer have a twofold risk of developing melanoma.
* A higher socioeconomic class has been linked to a higher incidence of melanoma, which Dr. Rigel attributes to this group being able to afford more vacations and leisure time that could result in more sun exposure.
* Airline flight personnel had a higher rate of melanoma when the incidence of melanoma was examined by occupation.
* Male drivers have been found to have a higher incidence of skin cancers on the left side of the body compared to right side of the body.
* Taller men were found to have a higher incidence of melanoma than shorter men, with men in the top quartile of height twice as likely to develop melanoma as men in the bottom quartiles of height.
* Use of tanning beds is a major risk factor for melanoma, with studies showing people who use tanning beds have a higher melanoma risk, a higher incidence of getting a second melanoma, and are younger when they develop melanoma.
* Patients with a history of dysplastic nevi, or non-cancerous moles that share some of the features of melanoma, and a family history of melanoma have a 50 percent greater risk of developing melanoma.

“Dermatologists continually look for clues as to who is most likely to develop melanoma, and this ongoing research will likely help more people understand their own risk factors and may convince them to get regular skin cancer screenings,” said Dr. Rigel. “Unfortunately, we expect skin cancer rates to continue to climb. But, identifying additional risk factors for melanoma could lead to the early detection and successful treatment of this potential killer.”

People who are known to have any of the risk factors for melanoma should regularly conduct skin self-examinations and see a dermatologist.

For more information on melanoma, go to the “SkinCancerNet” section of www.skincarephysicians.com, a Web site developed by dermatologists that provides patients with up-to-date information on the treatment and management of disorders of the skin, hair and nails.

Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 15,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails.

American Academy of Dermatology
888.462.DERM (3376)
www.aad.org

Source: AAD

PhotoMedex Introduces Neova Advanced Essential Lash™

Combat Thinning Lashes with Essential Copper

SAN FRANCISCO, CA, March 6, 2009 – PhotoMedex, Inc. (NASDAQ: PHMD) announced today that Procyte, a PhotoMedex company, will launch its new eyelash conditioner at the winter conference of the American Academy of Dermatology (AAD) in San Francisco. Neova Advanced Essential Lash™, formulated with Procyte’s patented AHK Copper Peptide Complex® technology, botanicals and essential amino acids, strengthens, conditions and hydrates thinning and brittle lashes. It is clinically proven to promote the appearance of fuller, thicker and longer eyelashes in as little as three weeks*. Safe and non-irritating, Essential Lash can be obtained through participating physicians without a prescription.

Procyte, the innovator of utilizing copper technology in skincare, brings the revolutionary benefits of the essential micronutrient to renew and restore health and vitality to natural eyelashes. The third most abundant trace metal in the human body, copper is essential for hair health. Procyte’s patented AHK Copper Peptide Complex utilizes a unique delivery system that mimics the body’s natural transport mechanisms to deeply nourish the hair follicle, resulting in eyelashes with a thicker, longer, darker appearance.

The Science Behind Lush Lashes: AHK Copper Peptide Complex®
• Proprietary AHK Copper Peptide Complex deeply nourishes and stimulates hair follicles with patented copper tripeptides
• AHK Copper Peptide technology uses a unique delivery system that mimics the body’s natural copper transport mechanisms
• AHK Copper Peptide technology provides a precise delivery of copper to the base of the eyelash follicles where it can stimulate cells responsible for production of substances such as collagens and various proteins
• AHK Copper Peptide technology stimulates the formation of extracellular matrix components which is important to the health of the hair follicle as it provides structural integrity, components and a nutrient supply

Benefits of Essential Lash
• Natural eyelashes will appear fuller, thicker and longer
• Strengthens and conditions eyelashes to protect from breakage
• Non-prescription formulation
• Does not contain prostaglandin
• Does not cause lid hyperpigmentation
• Does not cause iris discoloration
• Non-irritating; safe for sensitive eyes
• Hypoallergenic
• Physician tested; clinically tested
• Paraben free

Suggested Retail Price: $140
When applied nightly, Essential Lash (0.2 fl. oz.) will last approximately four to six months, averaging $28 per month – a considerably lower monthly cost compared to the market’s current prescription lash conditioner.

Availability: February 2009 at www.EssentialLash.com and through participating physicians.

*Data on file. Evaluator 8-week blinded study

About PhotoMedex
PhotoMedex is the market leader in developing proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC® laser system for the treatment of psoriasis, vitiligo, atopic dermatitis. PhotoMedex is also the market leader in developing and marketing products based on its patented, clinically proven Copper Peptide Complex® technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, and medical spas. The Company’s Procyte brands include Neova®, Ti-Silc®, Complex® Cu3, Tricomin®, GraftCyte®, Vitalcopper®, Simple Solutions® and AquaSante®.

PROCYTE - Copper. The science of skin care.
215.619.3600
www.procyte.com

Source: Procyte

Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex® Spray Followed by Vectical™ Ointment in Managing Plaque Psoriasis

Interim Findings To Be Presented in a Poster Session at the 67th Annual Meeting of the American Academy of Dermatology

SAN FRANCISCO, Calif., March 6, 2009 – Galderma Laboratories, L.P. today announced interim findings from a study of sequential treatment of plaque psoriasis using Clobex® (clobetasol propionate) Spray 0.05% followed by treatment with Vectical™ (calcitriol) Ointment 3mcg/g. The results of an interim analysis of the data are to be presented in a poster session at the 67th Annual Meeting of the American Academy of Dermatology on March 8th at 10:30 a.m. PT. The poster can be found under reference number 3362.

While both Clobex Spray and Vectical Ointment are indicated for the treatment of plaque psoriasis, this study was conducted to confirm the safety and efficacy of these products when used in a sequential regimen. In this study, Clobex Spray was used in the initial phase of the study to treat moderate to severe plaque psoriasis. For subjects sufficiently clear at the end of 4 weeks, Vectical Ointment was applied twice-daily for 8 weeks. Success was evaluated at week 12 based on Overall Disease Severity (ODS) scores.

The interim results indicate that sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Additionally, the interim results demonstrate that this sequential treatment regimen was well tolerated, with the most commonly reported side effects including mild to moderate pruritus (itching), stinging and burning and telangectasias (small dilated blood vessels near the surface of the skin).

“The recent availability of Vectical Ointment fulfills an important unmet need for patients who do not have access to a steroid-free ointment that can help manage their condition both safely and effectively over the long-term,” said Mark Lebwohl, M.D., Department of Dermatology, Mount Sinai School of Medicine, New York, and lead author of the study. “However, it is also exciting to have interim results that indicate the use of Clobex Spray followed by Vectical Ointment fits well within accepted and common psoriasis treatment regimens.”

“These study results reinforce our commitment to bringing safe and effective therapies to the millions of patients that suffer from psoriasis,” said Ron Gottschalk, M.D., Medical Director, Galderma Laboratories, L.P. “We look forward to reporting the final results of this study, which are expected to be published early next year. We believe this study will confirm that Vectical Ointment can help maintain, for at least 8 weeks, much of the gains seen when a high potency corticosteroid is used to initially treat moderate to severe plaque psoriasis.”

Important Safety Information About Clobex® (clobetasol propionate) Spray 0.05%
Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested. In controlled clinical trials, the following adverse reactions have been reported: burning, pruritus, dryness, pain, hyperpigmentation around resolving plaque, irritation and atrophy. Clobex® (clobetasol propionate) Spray, Lotion and Shampoo, 0.05% are not recommended for use on anyone younger than 18 years of age. Treatment should be limited to four consecutive weeks for psoriasis, and to two consecutive weeks for other SRDs. The total dosage for Spray should not exceed 50 g (59 mL or 2 fl oz) per week, and for Lotion and Shampoo should not exceed 50 g (50 mL or 1.75 fl oz) per week. Patients should use CLOBEX® (clobetasol propionate) Spray, Lotion, or Shampoo, 0.05%, only for the minimum period necessary to achieve desired results. It should not be used on the face, groin, or axillae.

Important Safety Information About Vectical™ (calcitriol) Ointment 3mcg/g
Vectical™ Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in patients 18 years and older. The most frequent adverse events reported in clinical trials (>3%) were lab test abnormality, urine abnormality, psoriasis, hypercalciuria and pruritus. Skin discomfort has also been reported. Vectical™ Ointment should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements, or who are on medications known to increase serum calcium levels, such as thiazide diuretics. If aberrations in parameters of calcium metabolism occur, Vectical™ Ointment should be discontinued until these normalize. Patients should be cautioned to avoid excessive exposure to natural or artificial sunlight after applying the ointment. If severe irritation occurs discontinue use. Avoid contact with eyes, lips and face. Vectical™ Ointment has not been studied in pregnant or nursing women. Use no more than 200 grams per week.

About Galderma
Galderma, created in 1981 as a joint venture between Nestle and L’Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company has a presence in 65 countries with over 1000 sales representatives and is committed to improving the health of skin with an extensive line of products across the world that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With a research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading worldwide dermatology brands include Differin®, Epiduo®, Oracea®, MetroGel® 1%, Rozex®, Clobex®, Tri-Luma®, Loceryl® and Cetaphil®.

Galderma
817.961.5000
www.galdermaUSA.com